UP - logo
E-resources
Full text
Peer reviewed
  • VANDA regimen followed by b...
    Heraudet, Luc; Galtier, Jean; Favre, Simon; Peyraud, Florent; Cazaubiel, Titouan; Leroy, Harmony; Mottal, Nathan; Gros, François‐Xavier; Forcade, Edouard; Clément, Laurence; Dumas, Pierre‐Yves; Pigneux, Arnaud; Leguay, Thibaut

    British journal of haematology, August 2022, Volume: 198, Issue: 3
    Journal Article

    Adults with relapsed or refractory B‐precursor acute lymphoblastic leukaemia (R/R BCP‐ALL) have very poor outcome. Blinatumomab as single agent has shown activity in R/R BCP‐ALL. We aimed to assess the activity of blinatumomab in concomitant association with intensive chemotherapy. Seventeen patients with R/R BCP‐ALL were treated with combination of blinatumomab and VANDA (etoposide, cytarabine, mitoxantrone, dexamethasone and asparaginase) regimen. Complete remission (CR) was achieved in 14/17 patient (82%) and 11/17 (65%) were transplanted. One‐year leukaemia‐free survival was 58.8% for the whole cohort and 90.9% for transplanted patients. These preliminary data suggest that the VANDA‐blinatumomab salvage regimen leads to a very high rate of CR and HSCT in suitable patients.